Tag: J&J

Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions

Now available in the U.S., the Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter safely modifies and crosses occlusive or extremely narrowed calcific peripheral artery disease SANTA CLARA, Calif., March 4, 2025 /PRNewswire/ — Today, Shockwave Medical, Inc., part of Johnson…

ACTION Centers Collaborate with Johnson & Johnson MedTech to Secure FDA Labeling for Impella Support System in Pediatric Patients

CINCINNATI, Dec. 13, 2024 /PRNewswire/ — In a groundbreaking achievement for pediatric heart care, the FDA has expanded the labeling of Johnson & Johnson MedTech’s Impella Support System to include treatment for certain children suffering from heart failure, extending the original…

Johnson & Johnson MedTech Receives FDA Approval for the VARIPULSE™ Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation

The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy1 Approval is supported by the admIRE study, where 85% peak primary…

Johnson & Johnson MedTech Completes Pilot Phase Enrollment of OMNY-AF Trial Evaluating Large-Tip, Focal Pulsed Field Ablation OMNYPULSE™ Catheter

The OMNY-AF trial evaluates safety and efficacy of the investigational OMNYPULSE™ Platform, a novel catheter that combines a large ablation area with mapping capabilities   Irvine, CA – October 30, 2024 – Today, Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced the enrollment completion of the […]

J&J Organizational Executive News: Celine Martin Appointed as Group Chairman, Cardiovascular & Specialty Solutions Group

On behalf of Johnson & Johnson, we have exciting organizational news to share, which will continue to help advance our mission to enable a healthier future for patients. Celine Martin has recently been appointed to the new role of Company Group Chairman, Cardiovascular & Specialty Solutions (CSS) Group. In this […]

Stereotaxis and Johnson & Johnson’s Biosense Webster Extend Development Alliance and Supply Agreement

ST. LOUIS, June 25, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has entered into an amendment to the long-term Development Alliance and Supply Agreement with Johnson & Johnson’s Biosense Webster, Inc. The amendment […]

Biosense Webster, Inc. Launches Study To Evaluate Novel High Power, Short Duration Modality For Treatment Of Atrial Fibrillation

IRVINE, Calif., May 2, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its QDOT AF Study.** The study will evaluate the delivery of high power, short duration ablation […]